Physician profile
Steven D Lenhard
NPI 1417940776
$11,906.65
in general payments reported to CMS, 2019-2025
42 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $1,444 · 2021: $1,890 · 2022: $2,501 · 2023: $2,373 · 2024: $1,774 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,993.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,504.86 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $1,477.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $982.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $977.50 | 2020-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $719.44 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $655.87 | 2021-2024 | Unithroid |
| Abbvie INC. | $561.67 | 2019-2025 | |
| Heartflow, INC. | $501.00 | 2022-2025 | |
| Glaxosmithkline, LLC. | $461.16 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $454.26 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $357.64 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $342.44 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $335.09 | 2022-2024 | |
| Dexcom, INC. | $262.60 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Astellas Pharma US INC | $230.85 | 2021-2025 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lenhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.